University of Cincinnati Medical Center Hemophilia Treatment Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Benton, Melody
NCT05695391: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting
3
19
US, RoW
Coagulation Factor VIIa (Recombinant)
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
06/25
07/25
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
NCT04724421: Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Available
N/A
US, RoW
Voxelotor, GBT440
Pfizer, Pfizer
Sickle Cell Disease
 
 
ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Janbain, Maissaa
NCT05695391: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting
3
19
US, RoW
Coagulation Factor VIIa (Recombinant)
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
06/25
07/25
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
VIP, NCT04146376: Von Willebrand Factor in Pregnancy () Study

Recruiting
N/A
110
US
Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid, Use of a postpartum diary and additional blood draws.
University of Washington, Ergomed, Octapharma
Von Willebrand Diseases
12/26
12/26
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Pennington, Sharon
ATHN 16, NCT04647227: SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Recruiting
4
55
US
coagulation factor VIIa [recombinant]-jncw, SEVENFACT
American Thrombosis and Hemostasis Network, LFB USA, Inc.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
09/26
03/27
GBT021601-021, NCT05431088: A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Active, not recruiting
2/3
429
Europe, US, RoW
Osivelotor, PF-07940367 or GBT021601
Pfizer, Pfizer
Sickle Cell Disease
10/28
10/28
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
PROSPECT, NCT04930445: Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

Terminated
N/A
262
US
Oxbryta® (voxelotor) 500mg Tablets, Voxelotor, Oxbryta®
Pfizer, Pfizer
Sickle Cell Disease
10/24
10/24
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Staber, Janice
NCT04770935: To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Completed
1
6
Europe, US
efanesoctocog alfa (BIVV001)
Bioverativ, a Sanofi company
Von Willebrand's Disease (VWD)
12/22
12/22
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Currie, Alison
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Pichon, Nicole
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35

Download Options